Study
Pancreatic cancer organoids recapitulate disease and allow personalized drug screening
| Study ID | Alternative Stable ID | Type |
|---|---|---|
| EGAS00001003369 | Other |
Study Description
We report derivation of 30 Patient-Derived Organoid lines (PDOs) from tumors arising in the pancreas and distal bile duct. PDOs recapitulate tumor histology and contain genetic alterations typical for pancreatic cancer. In vitro testing of a panel of 76 therapeutic agents revealed sensitivities currently not exploited in the clinic. The PRMT5 inhibitor EZP015556, shown to target MTAP negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP+ tumors. Taken together, the work presented here provides a platform to identify novel therapeutics to target pancreatic tumor cells using PDOs.
Study Datasets 3 datasets.
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD00001004528 |
This dataset contains 31 pancreatic organoid samples used in the 'organoid data of pancreatic cancers ' study
|
HiSeq X Ten | 31 |
| EGAD00001004529 |
This dataset contains 53 blood samples used as controls in study EGAXXXXX and EGAXXXXX
|
HiSeq X Ten | 53 |
| EGAD00001005217 |
RNA sequencing of 31 pancreatic cancer organiods
|
NextSeq 500 | 31 |
Who archives the data?
Publications
Citations
Retrieving...
Retrieving...
